• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by G1 Therapeutics Inc.

    8/19/24 7:02:21 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GTHX alert in real time by email
    SC 13G 1 g1therapeutics13g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

     

     

    G1 Therapeutics, Inc.

    (Name of Issuer)

     

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

     

    3621LQ109

    (CUSIP Number)

     

     

    August 7, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 

    CUSIP No. 3621LQ109

     

     

    1.Names of Reporting Persons.


    Beryl Capital Management LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 5,179,529

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 5,179,529

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 5,179,529

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.8%

     

    12. Type of Reporting Person (See Instructions) IA, OO

     2 

    CUSIP No. 3621LQ109

     

     

    1.Names of Reporting Persons.


    Beryl Capital Management LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 5,179,529

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 5,179,529

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 5,179,529

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.8%

     

    12. Type of Reporting Person (See Instructions) IA, PN

     3 

    CUSIP No. 3621LQ109

     

     

    1.Names of Reporting Persons.


    Beryl Capital Partners II LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)          

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 4,412,436

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 4,412,436

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 4,412,436

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 8.4%

     

    12. Type of Reporting Person (See Instructions) PN

     4 

    CUSIP No. 3621LQ109

     

    1.Names of Reporting Persons.


    David A. Witkin

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 5,179,529

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 5,179,529

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 5,179,529

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.8%

     

    12. Type of Reporting Person (See Instructions) IN, HC

     5 

    CUSIP No. 3621LQ109

    Item 1.

     

    (a)Name of Issuer

    G1 Therapeutics, Inc.

     

    (b)Address of Issuer's Principal Executive Offices

    700 Park Offices Drive, Suite 200, Research Triangle Park, NC 27709

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Beryl Capital Management LLC (“Beryl”), Beryl Capital Management LP (“Beryl GP”), Beryl Capital Partners II LP (the “Partnership”) and David A. Witkin (collectively, the “Filers”). Each Filer disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at:

    225 Avenue I, Suite 205, Redondo Beach, CA 90277

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Stock, par value $0.0001 per share (the "Stock").

     

    (e)The CUSIP number of the Issuer is: 3621LQ109

     

     

     6 

    CUSIP No. 3621LQ109

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[X] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E), as to Beryl and Beryl GP.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[X] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G), as to Mr. Witkin.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    The percentages reported in this Schedule 13G are based on 52,758,191 shares of Common Stock outstanding as of August 2, 2024, as reported in the Form 10-Q filed by the Issuer on August 8, 2024.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     7 

    CUSIP No. 3621LQ109

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Beryl is the investment adviser to the Funds and other accounts. Beryl is the general partner of Beryl GP, which is the general partner of one or more of the Funds. Mr. Witkin is the control person of Beryl.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Material to Be Filed as Exhibits

    Exhibit A Joint Filing Agreement.

    Item 11.Certification of Beryl, Beryl GP and Mr. Witkin.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of the Partnership.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     8 

    CUSIP No. 3621LQ109

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 19, 2024

     

    BERYL CAPITAL MANAGEMENT LLC  

    BERYL CAPITAL MANAGEMENT LP

     

          By: Beryl Capital Management LLC
            General Partner
    By:  /s/ Andrew Nelson      
      Andrew Nelson     By: /s/ Andrew Nelson
      Chief Operating Officer and CFO       Andrew Nelson
            Chief Operating Officer and CFO
    BERYL CAPITAL PARTNERS II LP    
         
    By: Beryl Capital Management LP   /s/ David A. Witkin
    General Partner   David A. Witkin
         
    By: Beryl Capital Management LLC    
    General Partner    
         
    By: /s/ Andrew Nelson    
    Andrew Nelson    
    Chief Operating Officer    
     9 

    CUSIP No. 3621LQ109

     

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G and Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Beryl Capital Management, LLC, a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

     

    Dated: August 19, 2024

     

    BERYL CAPITAL MANAGEMENT LLC  

    BERYL CAPITAL MANAGEMENT LP

     

          By: Beryl Capital Management LLC
            General Partner
    By:  /s/ Andrew Nelson      
      Andrew Nelson     By: /s/ Andrew Nelson
      Chief Operating Officer and CFO       Andrew Nelson
            Chief Operating Officer and CFO
    BERYL CAPITAL PARTNERS II LP    
         
    By: Beryl Capital Management LP   /s/ David A. Witkin
    General Partner   David A. Witkin
         
    By: Beryl Capital Management LLC    
    General Partner    
         
    By: /s/ Andrew Nelson    
    Andrew Nelson    
    Chief Operating Officer    

     

     

    Get the next $GTHX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GTHX

    DatePrice TargetRatingAnalyst
    1/30/2023$7.00 → $10.00Underweight → Neutral
    JP Morgan
    1/3/2023$32.00 → $31.00Buy
    Needham
    11/4/2021$20.00 → $19.00Neutral → Underweight
    JP Morgan
    11/4/2021$78.00 → $71.00Buy
    HC Wainwright & Co.
    11/4/2021$41.00 → $24.00Outperform
    Raymond James
    10/15/2021$51.00Buy
    BTIG Research
    9/30/2021$24.00 → $20.00Overweight → Neutral
    JP Morgan
    9/1/2021$57.00 → $56.00Buy
    Roth Capital
    More analyst ratings

    $GTHX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

      Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 20, 2024 /PRNewswire/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase in cancer cases and a 93% rise in cancer deaths among men by 2050. According to Our World in Data, cancer has overtaken cardiovascular diseases as the leading cause of death in several wealthy nations. Despite warnings from the American Cancer Society, which found that 44% of cancer deaths in U.S. adults are linked to lifestyle factors, troubling trends continue. Another study revealed that even light drinking is associated with an increase in cancer death

      9/20/24 11:08:00 AM ET
      $GTHX
      $HALO
      $ONCY
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer

      - Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - G1 Stockholders to Receive U.S. $7.15 Per Share in Cash - HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, and G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company focused on delivering next-generation therapies that improve the lives of those affected by cancer, today announced that Pharmacosmos A/S has successfully completed the previously announce

      9/18/24 8:54:59 AM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period

      HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, and G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company focused on delivering next-generation therapies that improve the lives of those affected by cancer, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") relating to Pharmacosmos' previously announced acquisition of G1 Therapeutics. The expiration of the waiting period occurred at 11:59 p.m. EST on September 4, 2

      9/5/24 6:30:00 AM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GTHX
    SEC Filings

    See more
    • SEC Form 15-12G filed by G1 Therapeutics Inc.

      15-12G - G1 Therapeutics, Inc. (0001560241) (Filer)

      9/30/24 7:54:55 AM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by G1 Therapeutics Inc.

      S-8 POS - G1 Therapeutics, Inc. (0001560241) (Filer)

      9/18/24 4:14:56 PM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by G1 Therapeutics Inc.

      S-8 POS - G1 Therapeutics, Inc. (0001560241) (Filer)

      9/18/24 4:13:56 PM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GTHX
    Leadership Updates

    Live Leadership Updates

    See more
    • G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel

      RESEARCH TRIANGLE PARK, N.C., May 22, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the appointment of Monica Thomas as its General Counsel and Chief Compliance Officer. Mrs. Thomas replaces Stillman Hanson who departed the Company in May 2023. "G1 is in the midst of an important period in our evolution, as we evolve our commercial and clinical capabilities to maximize the future value of COSELA® (trilaciclib) and ensure that all appropriate patients may have access to this important drug," said Jack Bailey, Chief Executive Officer of G1 Therapeutics. "As we do so, it is essential that we maintain our fundamental focus o

      5/22/23 4:45:22 PM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors

      RESEARCH TRIANGLE PARK, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the appointment of Norman E. "Ned" Sharpless, M.D., to its Board of Directors. For nearly 30 years, Dr. Sharpless has been committed to the fight against cancer, including serving as one of the scientific founders of G1 in 2008. He is an accomplished oncologist and seasoned public servant who has treated cancer patients, investigated the biologic basis of cancer, and has led academic institutions and government agencies, including most recently serving as Director of the National Cancer Institute (NCI) at the National Institutes of Health

      7/25/22 6:30:43 AM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors

      RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the appointment of Jacks Lee to its Board of Directors. For more than 30 years, Mr. Lee has developed extensive experience in manufacturing and supply chain management in the life sciences industry. Mr. Lee currently serves as Senior Vice President – Manufacturing & Supply of Merck & Co., Inc., a global premier research-intensive biopharmaceutical health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. "G1's Board of Directors comprises ex

      6/28/22 7:30:00 AM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GTHX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by G1 Therapeutics Inc.

      SC 13G - G1 Therapeutics, Inc. (0001560241) (Subject)

      8/19/24 7:02:21 PM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by G1 Therapeutics Inc. (Amendment)

      SC 13D/A - G1 Therapeutics, Inc. (0001560241) (Subject)

      2/21/24 4:30:39 PM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by G1 Therapeutics Inc. (Amendment)

      SC 13G/A - G1 Therapeutics, Inc. (0001560241) (Subject)

      2/9/23 11:19:27 AM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GTHX
    Financials

    Live finance-specific insights

    See more

    $GTHX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $GTHX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights

      - Entered into Definitive Merger Agreement to be Acquired by Pharmacosmos; Transaction Expected to Close in Late Third Quarter 2024 - - Achieved $15.8 Million in Net Revenue from Sales of COSELA® (trilaciclib) - - Drove Double Digit Quarter-Over-Quarter Growth in COSELA Vial Volume and Net Revenue - - Reaffirmed 2024 Net COSELA Revenue Guidance of Between $60 and $70 Million - - Due to the Pending Transaction with Pharmacosmos, G1 will Not Host a Conference Call and Webcast to Discuss the Second Quarter Financial Results and Business Update - RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today

      8/8/24 6:30:57 AM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharmacosmos Group to Acquire G1 Therapeutics

      - Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1's COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - Pharmacosmos' Significant Resources and Expertise in Hematology and Supportive Care to Maximize Availability of COSELA for Patients with ES-SCLC - - Transaction Expands and Strengthens Pharmacosmos' Global Commercial Portfolio - - G1's Shareholders to Receive U.S. $7.15 per Share in Cash for a Total Equity Value of Approximately $405 Million - RESEARCH TRIANGLE PARK, N.C. and HOLBAEK, Denmark, Aug. 07, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASD

      8/7/24 6:29:00 AM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

      RESEARCH TRIANGLE PARK, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the second quarter of 2024 on Thursday August 8, 2024, at 8:30 a.m. ET. To register for the event and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the company's website: www.g1therapeutics.com. The webcast will be ar

      7/25/24 11:15:18 AM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal & People Officer Thomas Monica R. returned 138,151 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - G1 Therapeutics, Inc. (0001560241) (Issuer)

      9/18/24 4:15:18 PM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Flowers Cynthia Louise returned 20,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - G1 Therapeutics, Inc. (0001560241) (Issuer)

      9/18/24 4:15:17 PM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Secor Alicia returned 20,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - G1 Therapeutics, Inc. (0001560241) (Issuer)

      9/18/24 4:15:19 PM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for COSELA

      Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB DIHYDROCHLORIDE has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity

      2/16/21 4:31:16 PM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for COSELA

      Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity

      2/16/21 11:21:53 AM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • February 12, 2021 - FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy

      For Immediate Release: February 12, 2021 Today, the U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer. Cosela may help protect bone marrow cells from damage caused by chemotherapy by inhi

      2/12/21 5:24:11 PM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GTHX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • G1 Therapeutics upgraded by JP Morgan with a new price target

      JP Morgan upgraded G1 Therapeutics from Underweight to Neutral and set a new price target of $10.00 from $7.00 previously

      1/30/23 7:33:11 AM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on G1 Therapeutics with a new price target

      Needham reiterated coverage of G1 Therapeutics with a rating of Buy and set a new price target of $31.00 from $32.00 previously

      1/3/23 11:04:19 AM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • G1 Therapeutics downgraded by JP Morgan with a new price target

      JP Morgan downgraded G1 Therapeutics from Neutral to Underweight and set a new price target of $19.00 from $20.00 previously

      11/4/21 7:46:08 AM ET
      $GTHX
      Biotechnology: Pharmaceutical Preparations
      Health Care